723 A phase 1, first-in-human, open-label, multicenter study of INCA32459, a bispecific anti–PD1 and anti–LAG-3 antibody, in patients with select advanced malignancies
Author:
Piha-Paul Sarina,Bourayou Nawel,Schaub Richard,Yang Yan-ou,Wei Wendy,Mayes Patrick,Gangadhar Tara
Publisher
BMJ Publishing Group Ltd